Literature DB >> 23338716

Significant correlation of TLR4 expression with the clinicopathological features of invasive ductal carcinoma of the breast.

Naureen Ehsan1, Sheeba Murad, Tamour Ashiq, Muhammad Uzair Mansoor, Summer Gul, Samra Khalid, Muhammad Younas.   

Abstract

Toll-like receptor 4 belongs to the family of pattern recognition receptors and is therefore an important part of innate immunity. Since the last decade, Toll-like receptors (TLRs) have gained much interest in cancer research due to their role in tumor progression. However, there is scarcity of data evaluating TLR4 expression in different cell populations of tumor in relation to clinicopathological parameters of invasive ductal carcinoma of the breast. Therefore, we investigated TLR4 expression in 50 primary invasive ductal carcinoma and 17 lymph node sections through immunohistochemistry. Significant association of TLR4 expression with local metastasis and absence of necrosis was observed. The incidence of lymph node metastasis was higher in patients with high TLR4 expression in the tumor cells. We also observed an interesting inverse relationship of TLR4 with necrosis. In endothelial and lymphocytic population constituting breast tumors, a significant association of TLR4 expression was seen with the tumor grade. Therefore, we conclude that TLR4 expression is of biological interest both as a prognostic marker as well as a possible therapeutic target.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23338716     DOI: 10.1007/s13277-013-0645-y

Source DB:  PubMed          Journal:  Tumour Biol        ISSN: 1010-4283


  46 in total

Review 1.  Innate immune recognition.

Authors:  Charles A Janeway; Ruslan Medzhitov
Journal:  Annu Rev Immunol       Date:  2001-10-04       Impact factor: 28.527

Review 2.  Toll-like receptors and innate immunity.

Authors:  R Medzhitov
Journal:  Nat Rev Immunol       Date:  2001-11       Impact factor: 53.106

Review 3.  Toll-like receptors in the induction of the innate immune response.

Authors:  A Aderem; R J Ulevitch
Journal:  Nature       Date:  2000-08-17       Impact factor: 49.962

4.  Increased Toll-like receptor 4 expression on T cells may be a mechanism for enhanced T cell response late after burn injury.

Authors:  Bruce Cairns; Robert Maile; Carie M Barnes; Jeffrey A Frelinger; Anthony A Meyer
Journal:  J Trauma       Date:  2006-08

5.  LPS-induced TLR4 signaling in human colorectal cancer cells increases beta1 integrin-mediated cell adhesion and liver metastasis.

Authors:  Rich Y C Hsu; Carlos H F Chan; Jonathan D Spicer; Mathieu C Rousseau; Betty Giannias; Simon Rousseau; Lorenzo E Ferri
Journal:  Cancer Res       Date:  2011-03-01       Impact factor: 12.701

6.  The tumor microenvironment of colorectal cancer: stromal TLR-4 expression as a potential prognostic marker.

Authors:  Rosaria Cammarota; Valentina Bertolini; Giuseppina Pennesi; Eraldo O Bucci; Ornella Gottardi; Cecilia Garlanda; Luigi Laghi; Massimo C Barberis; Fausto Sessa; Douglas M Noonan; Adriana Albini
Journal:  J Transl Med       Date:  2010-11-08       Impact factor: 5.531

7.  Bacterial lipopolysaccharide and IFN-gamma induce Toll-like receptor 2 and Toll-like receptor 4 expression in human endothelial cells: role of NF-kappa B activation.

Authors:  E Faure; L Thomas; H Xu; A Medvedev; O Equils; M Arditi
Journal:  J Immunol       Date:  2001-02-01       Impact factor: 5.422

8.  Trends in incidence rates of invasive lobular and ductal breast carcinoma.

Authors:  Christopher I Li; Benjamin O Anderson; Janet R Daling; Roger E Moe
Journal:  JAMA       Date:  2003-03-19       Impact factor: 56.272

Review 9.  Toll-like receptor 4 activation in cancer progression and therapy.

Authors:  Alja Oblak; Roman Jerala
Journal:  Clin Dev Immunol       Date:  2011-11-03

10.  TLR4 signaling induced by lipopolysaccharide or paclitaxel regulates tumor survival and chemoresistance in ovarian cancer.

Authors:  M Szajnik; M J Szczepanski; M Czystowska; E Elishaev; M Mandapathil; E Nowak-Markwitz; M Spaczynski; T L Whiteside
Journal:  Oncogene       Date:  2009-12-10       Impact factor: 9.867

View more
  11 in total

1.  Resistin facilitates breast cancer progression via TLR4-mediated induction of mesenchymal phenotypes and stemness properties.

Authors:  C-H Wang; P-J Wang; Y-C Hsieh; S Lo; Y-C Lee; Y-C Chen; C-H Tsai; W-C Chiu; S Chu-Sung Hu; C-W Lu; Y-F Yang; C-C Chiu; F Ou-Yang; Y-M Wang; M-F Hou; S-Sf Yuan
Journal:  Oncogene       Date:  2017-10-09       Impact factor: 9.867

2.  Significance of TLR4/MyD88 expression in breast cancer.

Authors:  Xiangjin Chen; Feng Zhao; Huihao Zhang; Youzhi Zhu; Kunlin Wu; Guozheng Tan
Journal:  Int J Clin Exp Pathol       Date:  2015-06-01

Review 3.  Mutations in components of antiviral or microbial defense as a basis for breast cancer.

Authors:  Bernard Friedenson
Journal:  Funct Integr Genomics       Date:  2013-09-21       Impact factor: 3.674

4.  Myeloid differentiation primary response gene 88-leukotriene B4 receptor 2 cascade mediates lipopolysaccharide-potentiated invasiveness of breast cancer cells.

Authors:  Geun-Soo Park; Jae-Hong Kim
Journal:  Oncotarget       Date:  2015-03-20

Review 5.  Toll-like receptor-4 modulation for cancer immunotherapy.

Authors:  Shanjana Awasthi
Journal:  Front Immunol       Date:  2014-07-25       Impact factor: 7.561

6.  Toll-like receptor 4 prompts human breast cancer cells invasiveness via lipopolysaccharide stimulation and is overexpressed in patients with lymph node metastasis.

Authors:  Huan Yang; Bo Wang; Tao Wang; Longjiang Xu; Chunyan He; Huiyan Wen; Jie Yan; Honghong Su; Xueming Zhu
Journal:  PLoS One       Date:  2014-10-09       Impact factor: 3.240

Review 7.  Trial Watch: Toll-like receptor agonists for cancer therapy.

Authors:  Erika Vacchelli; Alexander Eggermont; Catherine Sautès-Fridman; Jérôme Galon; Laurence Zitvogel; Guido Kroemer; Lorenzo Galluzzi
Journal:  Oncoimmunology       Date:  2013-06-10       Impact factor: 8.110

Review 8.  Should a Toll-like receptor 4 (TLR-4) agonist or antagonist be designed to treat cancer? TLR-4: its expression and effects in the ten most common cancers.

Authors:  Chun Wai Mai; Yew Beng Kang; Mallikarjuna Rao Pichika
Journal:  Onco Targets Ther       Date:  2013-11-05       Impact factor: 4.147

Review 9.  Toll-like receptor 4 in inflammation and angiogenesis: a double-edged sword.

Authors:  Sheeba Murad
Journal:  Front Immunol       Date:  2014-07-07       Impact factor: 7.561

10.  Toll-like receptor 4 as a predictor of clinical outcomes of estrogen receptor-negative breast cancer in Saudi women.

Authors:  Abdelhabib Semlali; Maroua Jalouli; Narasimha Reddy Parine; Abdullah Al Amri; Maha Arafah; Abdulrahman Al Naeem; Sanaa Abdullah Ajaj; Mahmoud Rouabhia; Mohammad Saud Alanazi
Journal:  Onco Targets Ther       Date:  2017-02-24       Impact factor: 4.147

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.